In recent years, pharmacy benefit managers (PBMs) have instituted programs to keep out-of-pocket drug costs high for patients. Why is the administration so eager to protect federal employees from high out-of-pocket costs but is perfectly happy for PBMs to enroll millions of other patients in these programs?
About Robert Popovian
This author has not written his bio yet.
But we are proud to say that Robert Popovian contributed 2 entries already.
Entries by Robert Popovian
The combination of legal disputes, a growing data repository and investigative reports have necessarily put the 340B Drug Pricing Program under the microscope. Combined with the fact that the policy lacks transparency, 340B has spiraled out of control to the point that no policymaker can ignore the need to look closer.